Publication: JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma
Issued Date
2016-06-01
Resource Type
ISSN
14765551
08876924
08876924
Other identifier(s)
2-s2.0-84959492009
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Leukemia. Vol.30, No.6 (2016), 1311-1319
Suggested Citation
M. L. Nairismägi, J. Tan, J. Q. Lim, S. Nagarajan, C. C.Y. Ng, V. Rajasegaran, D. Huang, W. K. Lim, Y. Laurensia, G. C. Wijaya, Z. M. Li, I. Cutcutache, W. L. Pang, S. Thangaraju, J. Ha, L. P. Khoo, S. T. Chin, S. Dey, G. Poore, L. H.C. Tan, H. K.M. Koh, K. Sabai, H. L. Rao, K. L. Chuah, Y. H. Ho, S. B. Ng, S. S. Chuang, F. Zhang, Y. H. Liu, T. Pongpruttipan, Y. H. Ko, P. L. Cheah, N. Karim, W. J. Chng, T. Tang, M. Tao, K. Tay, M. Farid, R. Quek, S. G. Rozen, P. Tan, B. T. Teh, S. T. Lim, S. Y. Tan, C. K. Ong JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia. Vol.30, No.6 (2016), 1311-1319. doi:10.1038/leu.2016.13 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/43038
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma
Author(s)
M. L. Nairismägi
J. Tan
J. Q. Lim
S. Nagarajan
C. C.Y. Ng
V. Rajasegaran
D. Huang
W. K. Lim
Y. Laurensia
G. C. Wijaya
Z. M. Li
I. Cutcutache
W. L. Pang
S. Thangaraju
J. Ha
L. P. Khoo
S. T. Chin
S. Dey
G. Poore
L. H.C. Tan
H. K.M. Koh
K. Sabai
H. L. Rao
K. L. Chuah
Y. H. Ho
S. B. Ng
S. S. Chuang
F. Zhang
Y. H. Liu
T. Pongpruttipan
Y. H. Ko
P. L. Cheah
N. Karim
W. J. Chng
T. Tang
M. Tao
K. Tay
M. Farid
R. Quek
S. G. Rozen
P. Tan
B. T. Teh
S. T. Lim
S. Y. Tan
C. K. Ong
J. Tan
J. Q. Lim
S. Nagarajan
C. C.Y. Ng
V. Rajasegaran
D. Huang
W. K. Lim
Y. Laurensia
G. C. Wijaya
Z. M. Li
I. Cutcutache
W. L. Pang
S. Thangaraju
J. Ha
L. P. Khoo
S. T. Chin
S. Dey
G. Poore
L. H.C. Tan
H. K.M. Koh
K. Sabai
H. L. Rao
K. L. Chuah
Y. H. Ho
S. B. Ng
S. S. Chuang
F. Zhang
Y. H. Liu
T. Pongpruttipan
Y. H. Ko
P. L. Cheah
N. Karim
W. J. Chng
T. Tang
M. Tao
K. Tay
M. Farid
R. Quek
S. G. Rozen
P. Tan
B. T. Teh
S. T. Lim
S. Y. Tan
C. K. Ong
Other Contributor(s)
National Cancer Centre, Singapore
Duke-NUS Medical School Singapore
Cancer Science Institute of Singapore
Duke University
Singapore General Hospital
Singapore Health Services
Sun Yat-Sen University Cancer Center
Tan Tock Seng Hospital
Yong Loo Lin School of Medicine
Chi Mei Medical Center
Taipei Medical University
Guangdong General Hospital
Mahidol University
SungKyunKwan University, School of Medicine
University of Malaya
Hospital Raja Permaisuri Bainun
National University Hospital, Singapore
A-Star, Genome Institute of Singapore
A-Star, Institute of Molecular and Cell Biology
Duke-NUS Medical School Singapore
Cancer Science Institute of Singapore
Duke University
Singapore General Hospital
Singapore Health Services
Sun Yat-Sen University Cancer Center
Tan Tock Seng Hospital
Yong Loo Lin School of Medicine
Chi Mei Medical Center
Taipei Medical University
Guangdong General Hospital
Mahidol University
SungKyunKwan University, School of Medicine
University of Malaya
Hospital Raja Permaisuri Bainun
National University Hospital, Singapore
A-Star, Genome Institute of Singapore
A-Star, Institute of Molecular and Cell Biology
Abstract
© 2016 Macmillan Publishers Limited. Epitheliotropic intestinal T-cell lymphoma (EITL, also known as type II enteropathy-associated T-cell lymphoma) is an aggressive intestinal disease with poor prognosis and its molecular alterations have not been comprehensively characterized. We aimed to identify actionable easy-to-screen alterations that would allow better diagnostics and/or treatment of this deadly disease. By performing whole-exome sequencing of four EITL tumor-normal pairs, followed by amplicon deep sequencing of 42 tumor samples, frequent alterations of the JAK-STAT and G-protein-coupled receptor (GPCR) signaling pathways were discovered in a large portion of samples. Specifically, STAT5B was mutated in a remarkable 63% of cases, JAK3 in 35% and GNAI2 in 24%, with the majority occurring at known activating hotspots in key functional domains. Moreover, STAT5B locus carried copy-neutral loss of heterozygosity resulting in the duplication of the mutant copy, suggesting the importance of mutant STAT5B dosage for the development of EITL. Dysregulation of the JAK-STAT and GPCR pathways was also supported by gene expression profiling and further verified in patient tumor samples. In vitro overexpression of GNAI2 mutants led to the upregulation of pERK1/2, a member of MEK-ERK pathway. Notably, inhibitors of both JAK-STAT and MEK-ERK pathways effectively reduced viability of patient-derived primary EITL cells, indicating potential therapeutic strategies for this neoplasm with no effective treatment currently available .